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The prevalence of diabetes increases with age, driven in
part by an absolute increase in incidence among adults
aged 65 years and older. Individuals with diabetes are at
higher risk for cardiovascular disease, and age strongly
predicts cardiovascular complications. Inflammation and
oxidative stress appear to play some role in the mech-
anisms underlying aging, diabetes, cardiovascular dis-
ease, and other complications of diabetes. However, the
mechanisms underlying the age-associated increase in
risk for diabetes and diabetes-related cardiovascular
disease remain poorly understood. Moreover, because
of the heterogeneity of the older population, a lack of
understanding of the biology of aging, and inadequate
study of the effects of treatments on traditional compli-
cations and geriatric conditions associated with diabe-
tes, no consensus exists on the optimal interventions for
older diabetic adults. The Association of Specialty Pro-
fessors, along with the National Institute on Aging, the
National Institute of Diabetes and Digestive and Kidney
Diseases, the National Heart, Lung, and Blood Institute,
and the American Diabetes Association, held a workshop,
summarized in this Perspective, to discuss current
knowledge regarding diabetes and cardiovascular dis-
ease in older adults, identify gaps, and propose questions
to guide future research.
In the U.S., approximately one in four adults aged 65
years or older has diabetes (1). Patients with diabetes are
at very high risk for developing cardiovascular disease
(CVD) and associated morbidity and mortality, and this
risk increases dramatically with age (2,3). Contributors to
CVD risk in diabetes include hyperglycemia, dyslipidemia,
obesity, insulin resistance, inflammation, hypertension,
autonomic dysfunction, and diminished vascular respon-
siveness. The Cardiovascular Health Study and others
have documented the CVD risk in diabetic patients, as
well as relevant associations in elderly populations, in
some detail (3,4). Although many interventions targeting
hypertension and dyslipidemia have been demonstrated
to reduce risk of CVD in individuals with diabetes, only
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limited data are available from studies directly testing the
effectiveness of these interventions in older populations
with diabetes (2,3). Thus far, interventions targeting hy-
perglycemia have had limited or no benefit on cardiovas-
cular risk reduction (reviewed in 3). Interventions to
prevent or delay progression from prediabetes to diabetes
in high-risk individuals have been effective, especially life-
style interventions in older individuals (5), but long-term
outcomes for cardiovascular events are not known.
This workshop brought together experts in diabetes,
diabetes-related CVD, and geriatric conditions (3). The pri-
mary goals of the workshop were to review current knowl-
edge and to identify key research areas to be addressed.
Discussions focused on clinical epidemiology of diabetes
and concomitant CVD in aging populations, including racial
and ethnic disparities in diabetes prevalence, metabolic
changes with age and their impact on diabetes, vulner-
abilities of the heart and blood vessels to aging with di-
abetes, and end-organ sequelae that lead to disability. The
workshop concluded with a thorough discussion of pre-
vention and treatments for CVD in older patients with
diabetes or prediabetes and unanswered research ques-
tions in this area.
EPIDEMIOLOGY OF DIABETES AND
CONCOMITANT CVD IN AN AGING POPULATION
Among adults aged 65 years or older in the U.S., the
combined prevalence of prediabetes and diabetes (both
diagnosed and undiagnosed) ranges from 50 to 80%,
depending on which measures of hyperglycemia are used
(1). Approximately $300 billion is spent annually on
patients with diabetes in the U.S., and the majority of
these costs is spent on older adults with long-standing
diabetes and severe complications (6). With the baby-boom
cohort reaching the geriatric age range, the number of new
diabetes cases is expected to increase, even if prevention
efforts are somewhat successful.
Prevalence of diagnosed and undiagnosed diabetes is
higher among Mexican Americans, African Americans,
and Asian Americans than it is among white Americans.
Although disparities are apparent in access to care in the
U.S., Diabetes Study of Northern California (DISTANCE)
data (see Table 1 for study names and descriptions) in-
dicate marked racial and ethnic disparities in the preva-
lence and incidence of diabetes and cardiovascular
outcomes, even in a population with uniform access to
care (7). Furthermore, there is substantial heterogeneity
within large ethnic groups. For example, incidence and
prevalence vary widely in subpopulations of Asian Amer-
icans. These disparities are similar between men and
women but recent evidence suggests that they are magni-
fied among adults older than 60 years.
Individuals with diagnosed diabetes are at higher risk
for coronary heart disease (CHD) (8), but CHD risk also is
elevated modestly among individuals with prediabetes, de-
fined as fasting plasma glucose concentrations of 100–125
mg/dL. Data from the National Diabetes Surveillance Sys-
tem indicate that the incidence of several diabetes-related
complications, including hyperglycemic death, amputation,
stroke, and ischemic heart disease (IHD), declined substan-
tially between 1989 and 2009, particularly among older
patients. Although relative glucose-related risk for CHD
appears to decrease with age (9), the overall absolute risk
for CVD increases dramatically with age (9), and age strongly
predicts diabetes-related congestive heart failure (CHF),
IHD, and stroke (Fig. 1).
Fasting plasma glucose concentration is a risk factor
for CVD. However, the association of fasting glucose with
Table 1—Names and characteristics of large clinical studies in diabetes
Acronym Study title Area of interest Study population Reference
ACCORD Action to Control Cardiovascular
Risk in Diabetes
Outcomes of hyperglycemia
treatment and lipid lowering
in diabetes




ADVANCE Action in Diabetes and Vascular
Disease
Outcomes of hyperglycemia
treatment and blood pressure
lowering in diabetes
11,140 patients with type 2
diabetes
46
BARI 2D Bypass Angioplasty
Revascularization Investigation
in 2 Diabetes
CAD treatment 2,368 patients with type 2
diabetes and heart disease
44
DISTANCE Diabetes Study of Northern
California
Health disparities More than 2 million adults enrolled
in Kaiser Permanente Northern
California in 2010, including more
than 210,000 patients with
prevalent diabetes and more than
15,000 incident cases in the
calendar year
7
DPP Diabetes Prevention Program Effects of lifestyle vs. metformin
on progression to diabetes
3,234 overweight individuals with
prediabetes
5
Look AHEAD Action for Health in Diabetes Effects of intervention on
cardiovascular morbidity and
mortality
5,145 overweight adults with
diabetes
38
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CHD is more moderate than other risk factors such as total
cholesterol, non-HDL cholesterol, and particularly systolic
blood pressure, which has a relationship with CHD that is
nearly log linear (8). The 2-h plasma glucose concentration
during an oral glucose tolerance test (OGTT) is a strong
determinant of cardiovascular risk. OGTT-defined predia-
betes and diabetes predict incidence of CVD and death,
even after accounting for corresponding categories based
on fasting plasma glucose (4). Duration of diabetes like-
wise appears to be an important determinant for the
development of CVD. Risk for heart failure or stroke is
higher among individuals with a history of diabetes than
among those newly diagnosed (10), and diagnosed di-
abetes is an equivalent risk factor to previous myocar-
dial infarction (MI) among men aged 60–79 years with
earlier—but not recent—onset diabetes (11).
COMMON AGE-ASSOCIATED METABOLIC
CHANGES AND THEIR IMPACT ON DIABETES
Insulin sensitivity appears to decline with age (12). Skel-
etal muscle is an important site of age-related insulin re-
sistance. Factors contributing to age-associated insulin
resistance include visceral adiposity and associated adipo-
kines and inflammation, oxidative stress, mitochondrial
dysfunction, and possibly an intrinsic decline in insulin
sensitivity in muscle fibers. One pathway linking aging,
muscle, and risks for diabetes and CVD is shown in Fig. 2.
Age-associated declines in protein synthesis and quality
result in accumulations of damaged proteins and impaired
muscle strength and quality at a time when accumulating
oxidative damage, DNA damage and degradation, and
declines in mitochondrial copy number and mitochondrial
protein synthesis render muscle mitochondria less able
to produce ATP (13). Notably, exercise increases insulin
sensitivity and reverses age-related declines in mitochon-
drial oxidative capacity and ATP production, and resistance
training increases the content of a novel PGC-1a splicing
isoform associated with hypertrophy and enhanced muscle
strength (14).
Another mechanism links aging, pancreatic b-cell
impairments, and diabetes risks. Even among people
with normal glucose tolerance, insulin secretion is im-
paired with age, possibly because of a decrease in pancre-
atic islet mass and b-cell proliferative capacity (reviewed
in 15). b-Cell impairments are progressively worse in pre-
diabetes and overt diabetes. Alterations in the expression
of cell-cycle proteins that control cellular senescence, such
as p16INK4A, might play a role in age-related declines in
b-cell function (15). Under conditions of uncomplicated
obesity and associated declines in insulin sensitivity,
b-cells can adapt by producing more insulin (15). How-
ever, metabolic stressors and increasing defects in glucose
regulation can overwhelm adaptive mechanisms. Thus,
diabetes is accompanied by a loss of functional b-cells
and a resulting decline in insulin secretion (16).
Older individuals with type 2 diabetes tend to be
overweight and deconditioned with central adiposity and
insulin resistance, which promote dyslipidemia and athero-
genesis (12) (Fig. 2). The metabolic abnormalities associated
with diabetic dyslipidemia include insulin resistance,
hypertriglyceridemia, an abnormal distribution of apoB-
enriched low-density and remnant lipoprotein particles,
and low HDL cholesterol. Excess fat deposition in the
liver in type 2 diabetes triggers the overproduction of
triglyceride- and apoB-enriched lipoproteins. Hepatic fat
accumulation also induces overproduction of inflamma-
tory proteins that alter levels of hepatic lipase, choles-
terol ester transfer proteins, and lipoprotein lipase.
These alterations lead to the remodeling of large, buoyant
LDL into small, dense, apoB-laden remnant lipoproteins
and the alteration of HDL composition into particles
Figure 1—Incidence (per 1,000) of major diabetes complications
among adults with diabetes, by age, 2009. Source: National Diabetes
Surveillance System, available from http://www.cdc.gov/diabetes.
CHF, congestive heart failure; ER, emergency room; ESRD, end-
stage renal disease; IHD, ischemic heart disease.
Figure 2—A proposed pathway linking aging, muscle, and risks for
diabetes and CVD. Source: Nair KS. Aging muscle. Am J Clin Nutr
2005;81:953–963. T2DM, type 2 diabetes mellitus.
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enriched in triglyceride and deficient in cholesterol ester
and apoA-I. This dysfunctional HDL exhibits reduced cho-
lesterol efflux, anti-inflammatory, antioxidative, and anti-
apoptotic capacity that activate macrophages and endothelial
and smooth muscle cells while the abnormal LDL rem-
nants are deposited into the vessel wall, accelerating
foam cell formation and atherogenesis (17). Ultimately,
insulin resistance and lipotoxicity enhance inflammation,
amyloid formation, macrophage proliferation, and smooth
and endothelial cell activation and thereby accelerate ath-
erogenesis and plaque formation further. These abnormal-
ities in HDL and LDL function may contribute to the
heightened inflammation, amyloid deposition, and in-
creased reactive oxygen species that also contribute to
b-cell failure (18). The effects of age on all these risk
factors, as well as on the primary and secondary mecha-
nisms underlying dyslipidemia and accelerated atheroscle-
rosis in individuals with type 2 diabetes, is a fertile area
for future investigation.
VULNERABILITIES OF THE HEART AND BLOOD
VESSELS TO AGING AND DIABETES
Even up to age 80, there are no substantial aging-related
changes in overall resting cardiac function, but there are
notable age-associated changes in specific aspects of cardiac
structure and cardiovascular function (Table 2). Lifestyle-
associated stressors, such as poor diet, physical inactivity,
and smoking, can accelerate these changes.
Diabetes also has a major impact on the heart (19,20).
Systolic and diastolic dysfunction and changes in coronary
blood flow in the presence of diabetes suggest that di-
abetes impairs the ability of the heart to use free fatty
acids as energy substrates. The impact of hyperglycemia
on left ventricular function can be influenced by many
factors, including sex, endothelial dysfunction, duration
of diabetes, alterations in cellular metabolism, and dys-
function in the autonomic nervous system. Diabetes can
worsen age-related changes in diastolic dysfunction by as
much as fivefold (19,20). It is not clear if microvascular
abnormalities contribute to overall cardiac dysfunction or
how the presence of diabetes affects responses to cardio-
vascular injury or infarct with aging.
The mechanisms underlying age- and diabetes-related
changes to the vasculature are not understood fully, but
inflammation and oxidative stress appear to play a synergis-
tic role. Aging arteries exhibit a chronic inflammatory profile
similar to that seen with atherosclerosis, hypertension, and
diabetes. Inflammation and oxidative stress together pro-
mote extracellular matrix remodeling, increased tone, and
intrinsic cell stiffness in the vascular smooth muscle.
Oxidative stress resulting from increased superoxide avail-
ability in the arteries, uncoupling of nitric oxide synthase,
and mitochondrial dysfunction also promotes endothelial
dysfunction (21,22). Angiotensin II plays a role in this syn-
ergy by mediating interactions among chronic inflammation,
mitochondrial dysfunction (21), longevity pathways (22),
and diabetes-related pathways. The effects of inhibiting an-
giotensin II signaling mimic those of caloric restriction (23).
While there may be an important role for adult stem cells
located in perivascular areas in maintaining endothelial
function, this topic was not discussed at the workshop.
Acute hyperglycemia does not appear to affect endo-
thelial function (24), but vessel function appears to be
impaired among individuals with type 2 diabetes. Dimin-
ished sympathetic nerve activity and insulin resistance are
possible factors, as insulin itself can be sympathoexcit-
atory. These effects might be counteracted by lifestyle
changes. Sodium restriction, caloric restriction, and weight
loss improve elastic artery compliance and vascular endo-
thelial function (25). Aerobic exercise partially preserves
vascular endothelial function and large elastic artery com-
pliance (26).
END-ORGAN SEQUELAE THAT LEAD TO
DISABILITY
Impaired vascular function can interact with diabetic
peripheral neuropathy (DPN) to cause foot ulcerations
and amputations. Hyperglycemia and advanced glycation
end products (AGEs) increase oxidative stress, which
activates kinases such as protein kinase C and increases
production of proinflammatory mediators, collagen, and
fibronectin (27). These pathways also deplete endothelial
and neural nitric oxide, leading to endothelial dysfunction
and damage to the vasa nervorum, thereby contributing
to nerve fiber injury and DPN. However, there are few
data on the interaction of DPN with the vasculature in
older adults with diabetes.
Although cognitive decline has not been viewed as
a traditional diabetes complication, type 2 diabetes
increases the risk for both vascular dementia and
Alzheimer disease (3,28). Diabetes and Alzheimer disease
pathology can exert synergistic effects with age on the
brain vasculature, blood flow, and delivery of substrates
necessary for cognition (29). The brain can be affected by
hyperglycemia, which increases production of AGEs and
their receptors, and by hypoglycemia, which creates exci-
totoxic insults and, in extreme cases, neuron cell death.
Defects in memory and executive function appear in
midlife and become progressively worse and disabling
Table 2—Age-related changes in the cardiovascular system
Heart
Slowing kinetics of diastolic filling
Left ventricular wall thickening
Left atrial enlargement
Augmentation in the atrial contribution to diastolic
ventricular filling
Decreased cardiovascular reserve function
Increased risk for arrhythmia
Altered regulation of cardiomyocyte calcium homeostasis
Arterial system
Diffuse intimal thickening
Stiffening of the aorta and carotid arteries
Endothelial dysfunction
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with older age, creating a cycle of increasing cognitive
impairment and poor self-management. Both type 2
diabetes and Alzheimer disease are associated with re-
duced cholesterol synthesis in the brain. Among middle-
aged adults with prediabetes and diabetes, areas of
glucose hypometabolism, gray matter atrophy, and re-
duced blood flow are apparent in the brain in a pattern
similar to that seen with Alzheimer disease (29,30). Obe-
sity, hypertension, and dyslipidemia influence age-related
risk for dementias (28,30), particularly in midlife. Around
the age of 70 years, however, mild elevations in blood
pressure, cholesterol, and weight appear to be associated
inversely with dementia, and work in animal models sug-
gests that these abnormalities might even be protective.
Alzheimer disease pathology, and particularly b-amyloid,
also may contribute to brain insulin resistance. b-Amyloid
induces insulin resistance by downregulating insulin
receptors from dendritic membranes, administration of
b-amyloid in nonhuman primates induces insulin resis-
tance in the hippocampus (31), and dietary induction of
mild insulin resistance in older human adults decreases
memory and increases b-amyloid levels and markers of
oxidative injury. In contrast, administration of insulin
blocks the synapse loss induced by b-amyloid (32), and
in an initial study, intranasal administration of insulin
improved memory and peripheral insulin sensitivity (33).
A large clinical trial of intranasal insulin is now under way
to test effects on cognition.
Diabetic kidney disease (defined as the presence of
albuminuria, an impaired glomerular filtration rate (GFR),
or both) occurs in approximately 35% of patients with
diabetes (34). The prevalence of diabetic kidney disease
increases with age, exceeding 50% among diabetic patients
aged 65 years or older. Diabetic kidney disease is associated
with longer duration of diabetes and with diabetes-related
complications, such as impaired lower-extremity function,
incident disability, and incident dementia. Diabetic kidney
disease contributes to the excess cardiovascular mortality
risk among patients with type 2 diabetes (35). Mechanisms
through which diabetic kidney disease contributes to CVD
are a subject of intensive current research.
PREVENTION AND TREATMENT FOR DIABETES
AND CVD
As suggested by the effects of exercise and dietary
changes on mitochondrial and vascular function, address-
ing lifestyle risk factors can have a substantial impact on
diabetes and CVD in the older population. In the Diabetes
Prevention Program (DPP), a clinical trial with individuals
at risk for type 2 diabetes, lifestyle intervention proved
especially effective in preventing diabetes among older
participants (Fig. 3), with a persistent effect for up to 10
years (5,36). These participants lost more weight, and
they showed a lower tendency, compared with middle-
aged participants, to regain the weight they had lost (5).
Obese, nondiabetic older adults randomized to dietary
interventions or exercise maintained weight loss up to 30
months following the study (37). Also, dietary changes
and exercise each improved parameters of physical func-
tion, but they exerted additive effects when combined.
These findings are consistent with those of the Look
AHEAD (Action for Health in Diabetes) study in middle-
aged and older people with type 2 diabetes, where weight
loss and improved fitness lowered the risk for loss of
mobility (38). Lifestyle interventions also improve intra-
hepatic fat content, insulin secretion, insulin sensitivity,
and metabolic risk factors for CHD (39), and they increase
the likelihood of partial remission of type 2 diabetes (40).
However, weight-loss interventions remain controver-
sial for older adults due to concerns that weight loss will
exacerbate sarcopenia and frailty and that attempts to
change lifelong habits will cause anxiety and distress. Yet
in DPP, otherwise healthy older adults were more active
and enthusiastic in adopting lifestyle changes and more
successful in achieving their goals (36). Older adults
with diabetes and multiple comorbidities can have both
sarcopenia and visceral obesity. In such individuals, weight
loss could exacerbate age-related declines in physical and
metabolic function, leading to development of the frailty
syndrome (3).
Treatment strategies used to address CVD risk factors
in younger populations with diabetes also apply to older
adults with diabetes. Clinical trials of interventions for
hypertension and lipid disorders in these populations
have been summarized (2,3). Consistent, positive out-
comes have been found in older people and people with
diabetes, but few studies have included enough older peo-
ple with diabetes to have adequate statistical power. Older
adults may in some cases be more sensitive to therapy
than younger adults. For example, in the Action to Con-
trol Cardiovascular Risk in Diabetes (ACCORD) trial, older
adults responded similarly to protocol-driven therapies as
younger participants did, and with some outcomes, such
as LDL cholesterol and triglyceride levels, older participants
Figure 3—Diabetes incidence rates by age-group in the DPP (36),
demonstrating the effectiveness of the lifestyle intervention vs. pla-
cebo, especially in the oldest age-group. Reprinted and modified by
permission of Oxford University Press on behalf of the Gerontolog-
ical Society of America.
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fared better than their younger counterparts. However, in
both the intensive and standard glycemia therapy arms of
the trial, these same older adults were more prone to severe
hypoglycemia than their younger counterparts. Although
ACCORD was stopped early because of excessive mortality
in the intensive therapy arm, this excessive mortality was
confined to participants younger than 65 years (41).
Primary percutaneous intervention (PCI) with drug-
eluting stent is the treatment of choice for acute coronary
syndromes, regardless of whether diabetes is present.
However, mortality and rates of MI and stroke are higher
among diabetic patients receiving PCI than among those
receiving coronary artery bypass graft (CABG) (42,43).
The Bypass Angioplasty Revascularization Investiga-
tion in 2 Diabetes (BARI 2D) study of patients with type
2 diabetes and coronary artery disease (CAD) showed no
significant difference in the rates of death and major
cardiovascular events between patients undergoing prompt
revascularization and those undergoing medical therapy
(44). Although the majority of participants in these stud-
ies were in their 60s and 70s, results were not stratified
by age.
Hypoglycemia
Impairment of protective mechanisms against hypoglyce-
mia (defined as a plasma blood glucose concentration
of 70 mg/dL or lower) is a serious issue in individuals
with diabetes (45). Such impairments may worsen with
duration of diabetes and most likely with age, and data
from the ACCORD trial suggest a relationship between
poor baseline cognitive function and the risk for severe
hypoglycemia, which requires the assistance of others for
recognition and treatment (Fig. 4) (41). Indeed, age is a
strong predictor of acute hypoglycemia. Concerns about
hypoglycemia and its potential impact are important fac-
tors in diabetes self-management. For example, patients
with diabetic kidney disease, and particularly those who
are older and receiving an intensive glucose-lowering regi-
men, are at increased risk for severe hypoglycemia (3).
However, severe hypoglycemia is a difficult outcome to
study, and mild hypoglycemia is almost never reported.
Thus, the potential impact of hypoglycemia is unclear.
Hypoglycemia increases QTc interval, production of proin-
flammatory markers, platelet activation, and markers of
oxidative stress, and it decreases endothelial function and
myocardial blood flow (3,45). Although these changes may
increase the risk for CVD and death, it is not clear that
hypoglycemia is a direct cause of these outcomes. Results
from several studies indicate a correlation between severe
hypoglycemia and future mortality (3,46). However, correl-
ative findings do not establish causality.
CHALLENGES TO INTERVENTION IN OLDER ADULTS
Predicting Outcomes and Competing Risk
Traditional mathematical models for assessing risk for
diabetes complications are based on the epidemiology and
Figure 4—Relationship between baseline cognitive function and risk for severe hypoglycemia in the ACCORD trial. Kaplan-Meier curves
are shown for the proportion of subjects with severe hypoglycemia events according to baseline tertiles of the Digit Symbol Substitution
Test (DSST) score. Crude incidence rates and 95% CIs are shown for each group. Log-rank test P 5 0.0001. Hazard ratios (HRs) for the
middle and highest score groups are with reference to the lowest DSST score group. Patients who scored in the worst tertile on the DSST
had the highest rate of severe hypoglycemia, at 2.90%/year or approximately 10% (proportion 0.10) cumulatively over 4 years. The
numbers below the x-axis are the actual number of patients in each tertile at each time point (41).
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natural history of diabetes, as well as on the transitions of
patients across their health status. Such models aid in the
assessment of competing risk by highlighting the inter-
actions between risks for diabetes complications and
nondiabetes events. Clinical trials have demonstrated
that the cardiovascular or mortality benefit of glycemic
or blood pressure control become apparent only after 5 to
10 years following treatment initiation (2,3). Although
most older diabetic patients have 5 or more years of
remaining life expectancy to benefit from interventions,
remaining life expectancy is important for diabetes care
decisions for those older patients near the end of life. A
simulation model, based in part on a mortality risk index
encompassing age, comorbidities, and functional status,
indicates that the expected benefit of glycemic control
declines as the levels of morbidity and functional impair-
ment increase (47). Studies of nationally representative
samples of older patients have found three naturally oc-
curring clusters of patients based on comorbidity, with
significant differences in mortality rates (3,48). Thus,
functional status and level of comorbidity are important
factors in assessing risk. Models of diabetes complications
would benefit from epidemiological data of older patients,
including data on geriatric complications, dementia, or other
conditions now known to be associated with diabetes.
Heterogeneity
The complexity of the older population with diabetes is
increased by several sources of heterogeneity. One is
general health status. In one study that stratified partic-
ipants by health status and age (48), the proportion of those
considered healthy was lower among participants aged older
than 75 years, compared with those aged 51–64 years
(Fig. 5). However, even among participants aged 51–64
years, 19% were expected to have difficulties in self-
management and an additional 7% were expected to
receive limited benefit from diabetes interventions be-
cause of the severity of their comorbidities. Conversely,
53% of diabetic patients aged older than 75 years were
relatively healthy. In addition, compared with nondia-
betic patients, diabetic participants in the Health and
Retirement Study (49) have much higher rates of
comorbidities, such as dementia or heart disease, begin-
ning in middle age. However, the relative impact of di-
abetes decreases with age. How to manage older diabetic
patients with severe physical impairments is not clear.
Diabetes management overall relies on patient prefer-
ences, as it occurs often in the absence of evidence or
consensus regarding appropriateness and quality of
interventions.
Racial and ethnic differences in subclinical disease,
disease burden, and access to care also contribute to
heterogeneity (50,51). A1C levels are higher among black,
Asian, and American Indian patients with diabetes. CVD
and CHF incidence are higher among black patients com-
pared with white individuals, but prevalence of coronary
calcifications is lower among black, Hispanic, and Asian
American individuals, and intima-media thickness is lower
among Chinese individuals. CAD burden is lower among
black and Hispanic patients, but black patients fare worse
after surgery, angioplasty, or coronary revascularizations
(50,51). Although all racial groups in the Get With the
Guidelines-Stroke program improve in response to inter-
ventions such as thrombolysis, deep vein thrombosis pro-
phylaxis, smoking cessation, antithrombotic medications,
atrial fibrillation and anticoagulation, and lipid therapy,
Figure 5—Heterogeneity in health status among patients with diabetes, based on data from the Health and Retirement Study of people
over age 50 (48). People with known diabetes were assigned to one of four mutually exclusive categories: a Very Healthy group with no
comorbidities; a healthy Intermediate group with comorbidities constrained to osteoarthritis and hypertension, and with no functional
impairments; a group for whom intensive diabetes management would be Difficult to Implement due to multiple comorbidities and/or any
one of the following: mild cognitive impairment, poor vision, two or more minor functional impairments; and a group with Uncertain Benefit
from intensive diabetes management due to having the poorest health status, with one or more of the following: moderate-to-severe
cognitive impairment, two or more major functional dependencies, and/or residence in a long-term nursing facility. As the Health and
Retirement Study is a U.S. population-based survey, the y-axis estimates the total number of people in the U.S. over age 50 with diabetes
in each category.
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Table 3—Questions for future research
Epidemiology 1. What is the extent to which associations between glycemia and CVD
events apply to the oldest adults?
2. In light of the high prevalence of undiagnosed diabetes and dysglycemia/
prediabetes in older adults, do heterogeneous glycemic subgroups matter
in terms of future risk, and what are their implications for screening?
3. Which subgroups are the best candidates for intervention?
4. Are the diabetes risk factors or their magnitudes of association different
for older adults than young and middle-aged adults?
5. What additional information is needed to improve risk stratification for
intervention?
6. What are significant racial/ethnic disparities in older adults with diabetes,
and what are the best approaches to address them?
7. To what extent are late-life health inequalities a legacy of early-life factors,
such as reduced access to care?
8. How will quality metrics distinguish between true racial/ethnic
inequalities in access to or quality of care vs. appropriate compliance
with geriatric recommendations for individualized care?
Pathophysiology 1. Are mechanisms of aging- and diabetes-related impairments of
pancreatic b-cell function similar or different? Additive or multiplicative?
2. Are any of these mechanisms reversible or preventable?
3. Would prevention of aging effects slow the progression to diabetes in at-
risk individuals?
4. How can insulin resistance be prevented?
5. What causes age-related declines in mitochondrial function, and how do
they and declines in insulin sensitivity and b-cell function contribute to
the age-related increase in risk for diabetes?
6. What causes age-related sarcopenia, and what is its impact on diabetes
progression and complications?
7. What are the independent and common mechanisms underlying the
interaction between advancing age and diabetes on arterial stiffness and
endothelial dysfunction, and how are they modulated by insulin
resistance, elevated glucose levels, and other common risk factors, such
as hyperlipidemia, abdominal obesity, or hypertension?
8. How does the resultant vascular dysfunction relate to CVD risk?
9. How does the myocardium change with age?
10. What is the time course of processes underlying diabetes and CVD, and
what is the trajectory of potential compensatory mechanisms?
11. Can medications associated with comorbidities contribute to the
pathophysiology of diabetes and risk for CVD complications?
12. What are the glucose-sensing mechanisms in the brain, and how are
they affected by age?
13. What changes are apparent in the prediabetic brain?
Complications and CVD risk 1. Do mild episodes of hypoglycemia affect CVD risk?
2. Does severe hypoglycemia affect nonfatal CVD outcomes in type 2
diabetes?
3. What mediates the relationship between severe hypoglycemia and
mortality risk? If this relationship is a marker of “vulnerability,” what
factors underlie such vulnerability?
4. What is the significance of hypoglycemia-induced changes in oxidative
stress, clotting, and inflammation?
5. Why do older patients with type 2 diabetes have a blunted
counterregulatory response and reduced symptoms of hypoglycemia?
6. What is the true relationship between mortality risk for older patients with
diabetes and the A1C level?
7. What are the mechanisms underlying non-CVD mortality in patients with
diabetes, and how do they relate to mechanisms underlying other
complications? How does the pathologic basis of diabetic kidney
disease compare with that for other complications?
8. How does the brain drive insulin and glucose metabolism in the
periphery?
Continued on p. 2586
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Table 3—Continued
Screening, diagnosis, and intervention 1. Should postload hyperglycemia be used as a screening tool to aid early
intervention?
2. What intervention measures can prevent age-related declines in
mitochondrial number/function?
3. Does the failure of glucose-lowering interventions to reduce CVD outcomes
arise from suboptimal targeting of therapies, particularly in older adults?
4. Is b-cell replacement therapy feasible in older patients?
5. What are the most effective preventive and treatment strategies for CVD? Does
prevention of or improvement in vascular dysfunction reduce risk of CVD?
6. Can targeted therapies and prevention approaches be developed to
address diabetic dyslipidemia and other risk factors for CVD?
7. What level of blood pressure elevation should be treated in patients with
diabetes, what drugs should be used, and by how much should blood
pressure be lowered?
8. How important is an aggressive lifestyle intervention in addressing
dyslipidemia in patients with diabetes?
9. What are potential beneficial pleiotropic effects of statin therapy in older
patients with diabetes, and should statins be used in patients aged older
than 80 years with diabetes?
10. Is there age-related cognitive impairment associated with statin therapy?
11. Should triglyceride and HDL cholesterol levels be addressed in older
patients with diabetes?
12. What are the best treatment options for diabetic patients with left main or
diffuse CAD?
13. What are the best treatment options for diabetic patients who have
received PCI and need repeat revascularization?
14. What are the best treatment options for diabetic patients who are at
higher risk for adverse outcomes associated with PCI or CABG?
15. How should the presence of diabetic kidney disease affect current clinical
management of diabetes?
16. Do novel kidney disease CVD pathways offer new opportunities for
intervention?
17. Can diabetic kidney disease be prevented or reversed, and does that
alter CVD risk?
18. How clinically effective and safe are lifestyle interventions in older adults?
19. What is the feasibility of lifestyle interventions in real-world settings?
20. Are the effects of lifestyle interventions maintained in the long term, and
what mechanisms and behaviors underlie such maintenance?
21. What are the mechanisms of action underlying the effects of weight loss,
and how do they differ from those underlying the effects of unintended
weight loss and frailty?
22. What are the mechanisms of action for nutraceutical or pharmacological
strategies, such as antioxidants, nitric oxide boosters, anti-inflammatory
agents, glucose/insulin-regulating or CVD risk-reducing drugs, and
modulators of energy-sensing pathways and mitochondrial function?
23. Are there racial and ethnic differences in screening for diabetes and
prediabetes?
24. Do differences in cultural beliefs and/or acculturation across minority
subgroups have an impact on lifestyle, medication adherence, and
outcomes?
25. What targeted interventions could further reduce health inequalities in
older patients after broadly effective preventive measures, such as risk
factor control and lifestyle changes, already have been applied
population-wide?
26. What is the impact of quality-improvement programs and culturally
tailored interventions in older adults with diabetes?
27. What other sources of heterogeneity are most important clinically, and
how can improved understanding of these sources be used to define and
choose new management strategies and set appropriate glucose and
cardiovascular targets?
28. Despite the presence of heterogeneity, can crosscutting, appropriate,
and high-quality diabetes care be defined?
29. Does the cost-effectiveness of prevention vs. treatment for type 2
diabetes differ by age?
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black patients are less likely than white patients to receive
these interventions (52).
Biological differences, such as family history and host
genetics, are another source of heterogeneity. The off-
spring of centenarians have an exceptionally longer health
span and are healthier and less likely to have diabetes or
CVD than age-matched control subjects (53). Likewise,
risk for diabetes and Alzheimer disease is lower for indi-
viduals with a parent who lived longer than 80 years.
Among individuals with exceptional longevity, enriched
genotypes include variants of FOXO3A, insulin growth
factor receptor, CETP, and apoC3. Other biological differ-
ences may include those in pathways underlying diabetes
complications or in age-related changes in fat, muscle, or
cognition.
Aging Biology and Pathophysiology: A Possible
Paradox
Restoring insulin sensitivity is a valid approach to treating
diabetes, but the risks associated with insulin resistance
are not always clear. Centenarians appear to have some
insulin resistance compared with their offspring and with
individuals who do not live as long (53), suggesting that
insulin resistance is not necessarily negative. In nematodes,
downregulation of the insulin receptor–like daf-2 confers
insulin resistance but prolongs life. In rat studies, insulin
sensitivity improves, even on ad libitum diets, when vis-
ceral fat is removed, and the animals live longer. However,
a recent summary of studies of insulin-sensitivity models
and longevity suggests that enhanced insulin sensitivity is
neither necessary nor sufficient for enhanced longevity in
mammals (54). It is possible then that age-related changes
in metabolic regulation, vascular function, and other pro-
cesses are accompanied by protective repair or adaptive
responses. In that case, attempts to reverse processes that
decline with age, such as insulin resistance, might provide
no benefit or even worsen outcomes.
FUTURE RESEARCH DIRECTIONS
The convergence of pathways underlying diabetes and
CVD on inflammation and oxidative stress suggests that
these age-related diseases might arise from a common
foundation. An overarching research question then is how
various mechanisms contributing to diabetes and CVD
affect and are affected by advancing age. Many other
potential research directions, including specific questions
listed in Table 3, also should be explored. In the past,
research has often examined pathways, organs, and sys-
tems independently. However, optimal health relies on
a balance of interrelated systems, and age or diabetes
may shift that balance. The mechanisms underlying the
cardiovascular, renal, nerve, and cognitive complications
of diabetes suggest a common microvascular pathway.
More research is needed on interactions between vascular
and cognitive abnormalities and on signaling between the
cardiovascular system and the brain. Increased under-
standing of the pathways common to diabetes, CVD,
and other morbidities might yield optimal treatments
for diabetes and its complications. More multidisciplinary
or interdisciplinary studies are needed.
Animal models of aging are needed to explore many of
these questions, keeping in mind that differences between
organisms can hamper the translation of observations.
Likewise, clinical trial populations are highly selected and
have largely excluded older individuals with diabetes so
that results are not generalizable to patients in everyday
practice. Improved predictive models, including those that
account for patient heterogeneity and can be used in real
practice, are needed for clinical trial participant selection.
Finally, intervention development has suffered because
epidemiologically powerful associations have not neces-
sarily been borne out in intervention trials. While clinical
end points and mortality remain important, future
studies also should include end points, such as functional
outcomes, that are of particular interest to older adults.
Thus, geriatricians should be involved in clinical trial
design and in achieving consensus on the best measures
and scales for assessment.
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